AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
mavorixafor 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| chemokine CXCR4 antagonists | 5820 | 558447-26-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Mavorixafor is a CXC Chemokine Receptor 4 (CXCR4) selective antagonist that blocks the binding of the CXCR4 ligand, stromal-derived factor-1α (SDF-1α)/CXC Chemokine Ligand 12 (CXCL12). SDF-1/CXCR4 plays a role in trafficking and homing of leukocytes to and from the bone marrow compartment. Gain of function mutations in the CXCR4 receptor gene that occur in patients with WHIM syndrome lead to increased responsiveness to CXCL12 and retention of leukocytes in the bone marrow. Mavorixafor inhibits the response to CXCL12 in both wild‑type and mutated CXCR4 variants associated with WHIM syndrome.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 26, 2024 | FDA | X4 Pharmaceuticals | |
| April 27, 2026 | EMA | Norgine B.V. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L03AX24 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS IMMUNOSTIMULANTS Other immunostimulants |
| FDA MoA | N0000182137 | Cytochrome P450 2D6 Inhibitors |
| FDA MoA | N0000182141 | Cytochrome P450 3A4 Inhibitors |
| FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
| FDA EPC | N0000194104 | CXC Chemokine Receptor 4 Antagonist |
| FDA MoA | N0000194105 | CXC Chemokine Receptor 4 Antagonists |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
Related Drugs by ATC class:
L03AX Other immunostimulants 15 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| WHIM syndrome | indication | 234571003 | DOID:0060591 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 100MG | XOLREMDI | X4 PHARMS | N218709 | April 26, 2024 | RX | CAPSULE | ORAL | 10610527 | Dec. 22, 2036 | TREATMENT OF PATIENTS 12 YEARS AND OLDER WITH WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS, AND MYELOKATHEXIS (WHIM) SYNDROME |
| 100MG | XOLREMDI | X4 PHARMS | N218709 | April 26, 2024 | RX | CAPSULE | ORAL | 11219621 | Dec. 22, 2036 | TREATMENT OF PATIENTS 12 YEARS AND OLDER WITH WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS, AND MYELOKATHEXIS (WHIM) SYNDROME |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 100MG | XOLREMDI | X4 PHARMS | N218709 | April 26, 2024 | RX | CAPSULE | ORAL | April 26, 2029 | NEW CHEMICAL ENTITY |
| 100MG | XOLREMDI | X4 PHARMS | N218709 | April 26, 2024 | RX | CAPSULE | ORAL | April 26, 2031 | TO INCREASE THE NUMBER OF CIRCULATING MATURE NEUTROPHILS AND LYMPHOCYTES IN PATIENTS 12 YEARS OF AGE AND OLDER WITH WHIM SYNDROME (WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS AND MYELOKATHEXIS) |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| C-X-C chemokine receptor type 4 | GPCR | ANTAGONIST | IC50 | 8.21 | DRUG LABEL | DRUG LABEL | |||
| Mu-type opioid receptor | GPCR | IC50 | 4.92 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | IC50 | 5.39 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | IC50 | 5.12 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| CHEMBL518924 | ChEMBL_ID |
| C494414 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB05501 | DRUGBANK_ID |
| 4043154 | VANDF |
| C2930725 | UMLSCUI |
| CHEBI:138865 | CHEBI |
| A1D8L | PDB_CHEM_ID |
| 10724 | INN_ID |
| 11256587 | PUBCHEM_CID |
| 384848 | MMSL |
| 42806 | MMSL |
| d10186 | MMSL |
| 019739 | NDDF |
| 8580 | IUPHAR_LIGAND_ID |
| 0G9LGB5O2W | UNII |
| 2684021 | RXNORM |
| D11510 | KEGG_DRUG |
| 0G9LGB5O2W | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| XOLREMDI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83296-100 | CAPSULE, GELATIN COATED | 100 mg | ORAL | NDA | 29 sections |